Strumento inattivo

Altre lingue Tiziana Life London S.E.

Azioni

TILS

GB00BKWNZY55

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Tiziana Life Sciences Gets $3.4 Million in Funding for Neurodegenerative Disease Studies	28/06
Tiziana Receives $3.4 Million in Non-Dilutive Funding	28/06
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's disease with Foralumab	27/06
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab	26/06
Social Buzz: Wallstreetbets Stocks Mixed Premarket Monday; Nvidia to Decline, Micron Technology to Open Higher	24/06
Tiziana Says FDA Accepts Fast Track Label Submission For Multiple Sclerosis Treatment	11/06
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis	11/06
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis	11/06
Tiziana Life Sciences' Foralumab Demonstrates Qualitative Improvement in Multiple Sclerosis Patients After 6 Months Use	06/06
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab	06/06
Tiziana Life Sciences, Ltd. Announces Qualitative Results for All 10 Non-Active Secondary Progressive Multiple Sclerosis (Na-Spms) Patients Enrolled in the Intermediate-Size Patient Population Expanded Access (Ea) Program	06/06
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab	04/06
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research	30/05
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab	13/05
Tiziana Life Sciences Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	10/05
MEDIA: MS News Today: Foralumab found to ease fatigue in SPMS patients in access program	25/04
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	25/04
Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	25/04
Sector Update: Health Care Stocks Rise in Afternoon Trading	23/04
Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program	23/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Tiziana Life London S.E.

Azioni

TILS

GB00BKWNZY55

Altre lingue

Filtri